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Abstract
Background: It is unclear whether individualized treatments based on biological factors have improved the
prognosis of recurrent breast cancer. The purpose of this study is to evaluate the survival improvement of patients
with recurrent breast cancer after the introduction of third generation aromatase inhibitors (AIs) and trastuzumab.
Methods: A total of 407 patients who received first diagnosis of recurrent breast cancer and treatment at National
Kyushu Cancer Center between 1992 and 2008 were retrospectively evaluated. As AIs and trastuzumab were
approved for clinical use in Japan in 2001, the patients were divided into two time cohorts depending on whether
the cancer recurred before or after 2001. Cohort A: 170 patients who were diagnosed between 1992 and 2000.
Cohort B: 237 patients who were diagnosed between 2001 and 2008. Tumor characteristics, treatments, and
outcome were compared.
Results: Fourteen percent of cohort A and 76% of cohort B received AIs and/or trastuzumab (P < 0.001). The
median overall survival (OS) times after breast cancer recurrence were 1.7 years and 4.2 years for these respective
cohorts (P < 0.001). Both the time period and treatment of AIs and/or trastuzumab for recurrent disease were
significant prognostic factors in multivariate analysis (cohort B vs. cohort A: HR = 0.70, P = 0.01; AIs and/or
trastuzumab for recurrent disease: yes vs. no: HR = 0.46, P < 0.001). When patients were categorized into 4
subgroups by the expression of hormone receptor (HR) and HER-2 status, the median OS times of the HR-positive/
HER-2-negative, HR-positive/HER-2-positive, HR-negative/HER-2-positive, and HR-negative/HER-2-negative subtypes
were 2.2, 2.4, 1.6, and 1.0 years in cohort A and 4.5, 5.1, 5.0, and 1.4 years in cohort B.
Conclusions: The prognosis of patients with recurrent breast cancer was improved over time following the
introduction of AIs and trastuzumab and the survival improvement was apparent in HR- and/or HER-2-positive
tumors.
Background
Molecular targeting therapies have recently become avail-
able, and tailored treatments based on individual biological
f a c t o r sh a v ea l r e a d yc o m et op l a ya ni m p o r t a n tr o l ei n
breast cancer treatment. In the adjuvant setting, a meta-
analysis has shown that 5-year adjuvant treatment with
tamoxifen (TAM) reduced the annual risk of recurrence
and death by more than 30% in patients with estrogen
receptor (ER)-positive tumors [1]. In addition, large rando-
mized controlled trials have shown that third-generation
aromatase inhibitors (AIs) are more effective than TAM
in post-menopausal early breast cancer patients with
HR-positive tumors [2-4]. Among women with HER-2-
positive early breast cancer, concurrent or sequential use
of trastuzumab with, or after, adjuvant chemotherapy sig-
nificantly improves both disease-free survival and overall
survival rates [5-7]. Adjuvant trastuzumab therapy is
expected to decrease the breast cancer mortality rate and,
as mentioned above, tailored treatments based on indivi-
dual biological factors have significantly contributed to the
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cancer [8].
Compared with the adjuvant setting, the type of tai-
lored treatments (based on biological factors) that have
contributed to the improvement in prognosis for
patients with recurrent or advanced breast cancer is less
clear. Some retrospective studies have reported that the
survival of patients with recurrent breast cancer has
improved, over time, with the introduction of new drugs
[9-12]. And while it is difficult to ascertain exactly
which therapies have contributed to the improved survi-
val of patients with advanced breast cancer [13], the
improvement does seem to be associated with the
expression of certain biological factors. Andre et al.
(2004) compared the prognosis of metastatic breast can-
cer patients over two time periods, and showed a signifi-
cant prolongation of survival over time in patients with
HR-positive tumors [14]. This finding suggests that the
improvement was related to therapy targeted at patients
who had HR-positive tumors. A recent study of an insti-
tutional-based review showed that women with HER2/
neu-positive disease who received trastuzumab had
improved prognosis compared with women with HER2/
neu-negative disease [15]. With the introduction of tras-
tuzumab in daily practice, the survival of patients with
HER-2-positive disease may be prolonged overtime.
Here, we investigate whether the survival of women
with recurrent breast cancer has improved following the
introduction of new agents, such as AIs and trastuzu-
mab. The use of these drugs for the treatment of recur-
rent, or metastatic, breast cancer in Japan was approved
in 2001. Thus, we compared the prognosis between
patients first diagnosed with recurrent breast before
2001 and those first diagnosed after 2001.
Recent studies have shown that intrinsic subtypes are
important prognostic and predictive factors in breast
cancer. Thus, in both early and advanced stage breast
cancer, the intrinsic subtype has been strongly correlated
with prognosis [16-18]. In a neoadjuvant setting, chemo-
sensitivity has been shown to differ among breast cancer
subtypes [19,20]. Thus, we also performed an exploratory
analysis to determine whether the recent survival
improvement in recurrent breast cancer was related to
the breast cancer subtype. We classified the patients into
four subgroups for this purpose: HR-positive/HER-2-
negative; HR-positive/HER-2-positive; HR-negative/HER-
2-positive; and HR-negative/HER-2-negative cases.
Within each subgroup, we compared the prognosis over
time, and evaluated the relationship between the survival
improvement and expression of HR and HER-2.
Methods
All patient data were collected at the Department of
Breast Oncology at the National Kyushu Cancer Center,
Fukuoka, Japan. This retrospective analysis was per-
formed in accordance with the ethical regulations of the
National Kyushu Cancer Center.
Study Design
A total of 569 patients who were diagnosed and treated
for recurrent breast cancer at the National Kyushu Can-
cer Center between 1992 and 2008 were eligible for this
study. All patients had undergone primary surgery for
breast cancer without any evidence of distant metastasis
and then were clinically determined to have recurrent
breast cancer. The diagnosis of recurrent disease was
essentially confirmed by physical examination, X-rays,
computer tomography (CT), magnetic resonance ima-
ging (MRI), bone scintigraphy and/or other imaging
modalities. A biopsy of metastasis was not essential for
the diagnosis of recurrent disease. We excluded 133
(23.3%) cases that lacked either HR or HER-2 expression
data, and 29 (5.1%) cases that were not followed-up, or
who did not receive treatment after first diagnosis of
recurrence. The remaining 407 patients were included
in the study. Isolated ipsilateral breast cancer recurrence
was excluded from the study because it was difficult to
distinguish true recurrence from a new primary lesion.
The clinicopathological factors and treatments for pri-
mary breast cancer and recurrent disease pertaining to
these patients were entered prospectively into the hospi-
tal database. Patients were assigned to two cohorts
based on the time of their first diagnosis of recurrence.
Cohort A included patients diagnosed between 1992
and 2000; Cohort B included patients diagnosed
between 2001 and 2008. As outlined above, patients
were also assigned to four subgroups according to HR
and HER-2 expression. The prognosis of the patients
within each group was compared between the two time
periods. Survival time was defined as the time from the
date of first recurrence to the last follow-up examina-
tion, or death. Follow-up was ended in December 2009.
T h ep r i m a r ya i m so ft h i ss t u d yw e r et oe v a l u a t et h e
association between period of diagnosis of recurrent dis-
ease and overall survival (OS). As an exploratory analy-
sis, we also determined the relationship between the
survival improvement over time and the breast cancer
subtype as defined by HR and HER-2 status.
Variables
Because prognostic variables were unevenly divided
between the two main cohorts, a multivariate model was
created to determine any association between these
cohorts and survival rate, after accounting for other
prognostic factors. Information regarding the year of
first recurrent diagnosis, patient age, primary tumor
size, number of positive axillary lymph nodes, HR status,
HER-2 status, relapse free interval (RFI), sites of
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ical treatments for recurrent disease was obtained
directly from the database.
ER and/or progesterone receptor assays were per-
formed using either an enzyme immunoassay method
(ELISA) or immunohistochemical analysis (IHC). HER-2
status was estimated by either IHC or fluorescence
in situ hybridization (FISH) at diagnosis, however most
cases were evaluated by IHC. HER-2 FISH were per-
formed for patients in Cohort B. Cases showing overex-
pression of HER-2/c-erbB2, or HER-2 amplification,
were considered to be HER-2-positive. Patients present-
ing with lung and/or liver and/or brain involvement
were classified as having visceral metastases. Patients
presenting with other involvements were classified as
having non-visceral metastases. There was no limitation
on the number or the type of treatments that each
patient received.
Statistical Analysis
Associations between the two cohorts and clinicopatho-
logical parameters were analyzed using a Chi-square test
for categorical variables, and the Wilcoxon rank sum
test for continuous variables. Kaplan-Meier survival
curves were plotted, and compared using the log-rank
test. Cox proportional hazard models were used for
both univariate and multivariate analyses. We analyzed
new systemic treatment (AI and/or trastuzumab) for
recurrent disease as a confounder in the Cox regression
model in order to clarify whether introduction of these
new agents was the main contributor to the survival
improvement over time. The hazard ratios (95% CI) and
P values were reported. All tests were two-sided, and P
< 0.05 was considered statistically significant. Statistical
analyses were carried out using SPSS II software (Ver-
sion 11 for Windows; SAS Institute, Tokyo).
Results
Patient characteristics
Cohort A contained 170 patients and cohort B con-
tained 237 patients. The median observation time was
2.7 years for cohort A and 3.1 years for cohort B. There
have been 286 deaths among the 407 patients. The dis-
tribution of patient characteristics within cohorts A and
B is shown in Table 1. In all patients, HER-2 status was
assessed by IHC and 102 patients (25%) were diagnosed
with HER-2/c-erb-B2 overexpressing tumors. Two
patients were diagnosed as having HER-2-amplified
tumors by fluorescence in situ hybridization. The two
cohorts were similar in terms of age at diagnosis of
recurrence, primary tumor size, HER-2 over-expression,
adjuvant treatments, and the site of first recurrence.
There were differences in the number of axillary lymph
nodes involved (≤ or >3 nodes), HR status, and RFI
between the two cohorts. Patients with recurrent disease
in cohort B tended to have less lymph node metastases,
were more likely to have HR-positive disease, and had a
longer disease-free interval compared with those in
cohort A. In this study, 3 of the 60 patients with HER-
2-positive disease (5%) received trastuzumab and 22 of
the 167 patients with HR-positive disease (13%) received
aromatase inhibitors as adjuvant therapy in cohort B. In
these populations, the effect of these new agents may be
attenuated. However, it has been shown that the use of
trastuzumab is still effective when continued beyond
disease progression [21] and that a change to a different
AI is effective after the failure of another AI [22]; there-
fore, we decided to include these patients in this
analysis.
Treatments received by patients within the two cohorts
The chemotherapy drugs, endocrine therapy agents, and
trastuzumab prescribed for the treatment of recurrent
disease within the two cohorts are shown in Table 2.
Only the agents that were used commonly and approved
in Japan were reviewed. Because AI, trastuzumab, cape-
citabine and vinorelbine were approved after 2001, and
taxanes were approved in the late 1990s, there are sig-
nificant differences in the frequency of use of these
agents between the two cohorts. Twenty-two percent of
cohort B, and 2.9% of cohort A, were treated with tras-
tuzumab (P < 0.01). In this analysis, most patients with
HER-2-positive tumors received trastuzumab-based
treatment beyond the time of disease progression and
the median number of trastuzumab treatment was 2.1
(range, 1-5). Fifty-six patients with HER-2-positive
tumors received trastuzumab treatment. AIs were given
to 55% of cohort B and 11% of cohort A (P < 0.01).
One hundred forty-four patients with HR-positive
tumors received AI treatment. The taxanes (46% vs.
25%, P < 0.01), capecitabine (42% vs. 7.6%, P < 0.01),
and vinorelbine (25% vs. 2.4%, P < 0.01) were used more
commonly in cohort B. Another trend was the reduced
use of anthracyclines (22% vs. 48%, P < 0.01), tamoxifen
(26% vs. 38%, P = 0.01), medroxyprogesterone acetate
(15% vs. 47%, P < 0.01) and mitomycin (0.8% vs. 49%,
P < 0.01) in cohort B.
Survival of recurrent breast cancer patients within the
two cohorts
In this unadjusted analysis, there was a significant
improvement in survival rate for women diagnosed with
recurrent breast cancer after 2001. The median survival
time increased from 1.7 years in cohort A to 4.2 years
in cohort B (Figure 1; P < 0.001). The 3-year survival
rate increased from 28% in cohort A to 61% in cohort
B, and the 5-year survival rate increased from 12% in
cohort A to 41% in cohort B.
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rence, brain metastasis, relap s ef r e ei n t e r v a l ,h o r m o n e
status, time period of recurrent breast cancer (pre- or
post-2001), T stage, number of involved lymph nodes,
adjuvant endocrine therapy, and used of AI and/or tras-
tuzumab for treatment of recurrent disease were all
associated with overall survival rates after breast cancer
recurrence (Table 3). Because the distribution of patient
characteristics differed between the two cohorts, a mul-
tivariate analysis was also performed. Both the time per-
iod and AI/trastuzumab treatment remained significant
prognostic factors (cohort B vs. cohort A: HR = 0.70,
P = 0.01; AIs and/or trastuzumab for recurrent disease:
yes vs. no: HR = 0.46, P < 0.001). The presence of visc-
eral metastases, brain metastasis, HR status, and T stage
and the number of axillary metastases were also found







Characteristic No. of Patients % No. of Patients % No. of Patients %
Median age, years 51.0 53.8 52.6
T stage
T1-T2 126 74.1 178 75.1 304 74.7
T3-T4 40 23.5 51 21.5 91 22.4
Unknown 4 2.4 8 3.4 12 2.9
No. of axillary nodes involved
≤3 nodes 96 56.5 139 58.6 235 57.7
>3 nodes 70 41.2 80 33.8 150 36.9
Unknown 4 2.4 8 3.4 12 2.9
Hormonal status
Negative 75 44.1 70 29.5 145 35.6
Positive 95 55.9 167* 70.5 262 64.4
HER-2 status
Negative 126 74.1 177 74.7 303 74.4
Positive 44 25.9 60 25.3 104 25.6
Subtype
HR + and HER-2 - 72 42.4 133* 56.1 205 50.4
HR + and HER-2 + 23 13.5 34 14.3 57 14.0
HR - and HER-2 + 21 12.4 26 11.0 47 11.5
HR - and HER-2 - 54 31.8 44* 18.6 98 24.1
Relapse Free Interval
≤ 2 yr 81 47.6 84* 35.4 165 40.5
>2 yr 89 52.4 153 64.6 242 59.5
Site of first recurrence
non visceral 77 45.3 124 52.3 201 49.4
visceral 93 54.7 113 47.7 206 50.6
Brain metastasis at diagnosis
no 163 95.9 224 94.5 387 95.1
yes 6 3.5 12 13.0 18 4.4
Adjuvant chemotherapy
no 59 34.7 65 27.4 124 30.5
yes 111 65.3 172 72.6 283 69.5
Adjunvant endocrine therapy
no 80 47.1 92 38.8 172 42.3
yes 90 52.9 145 61.2 235 57.7
*P < .05.
Abbreviations: HR, hormone receptor; HER-2, human epidermal growth factor receptor 2.
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tus was associated with prognosis in the multivariate
analysis and adjuvant endocrine therapy was not asso-
ciated with survival after disease recurrence.
Influence of HER-2 and HR status on survival between the
two cohorts
We also performed a subgroup analysis in order to
explore the association between the recent improvement
in the survival of recurrent breast cancer patients and the
breast cancer subtype as determined by HR and HER-2
status. For this purpose, patients were categorized into
four subgroups based on their HR and HER-2 expression
patterns. There have been 133 deaths among patients
of the HR-positive/HER-2-negative subgroup; 34 deaths
in the HR-positive/HER-2-positive subgroup; 32 deaths
in the HR-negative/HER-2-positive subgroup; and 87
deaths in the HR-negative/HER-2-negative subgroup.
The Kaplan-Meier curves illustrating the overall survival
rates for each subgroup within the two cohorts are
shown in Figure 2. For the HR-positive/HER-2-negative
subgroup, the median survival in cohort A was signifi-
cantly lower than that in cohort B (2.2 vs. 4.5 years, P <
0.001; Figure 2A; n = 205). For the HR-positive/HER-2-
positive subgroup, the survival rate within cohort A was
significantly lower than in cohort B (2.4 vs. 5.1 years, P =
0.001; Figure 2B; n = 57). For the HR-negative/HER-2-
positive subgroup, the median survival rate within cohort
A was significantly lower than that in cohort B (1.6 vs.
5 . 0y e a r s ,P<0 . 0 0 1 ;F i g u r e2 C ;n=4 7 ) .I nc o n t r a s t ,f o r
the HR-negative/HER-2-negative subgroup, the prognosis
remained poor over time and no significant survival
improvement was seen between the two cohorts (1.0 vs.
1.4 years, P = 0.18, Figure 2D; n = 98). To clarify the
effect of time period and AI/trastuzumab treatment on
survival in each subtype, multivariate analyses in the 4
subgroups were performed (Table 4). When AI/trastuzu-
m a ba n dt h et i m ep e r i o dw e r ei n c l u d e di nt h es a m e
model, AI and/or trastuzumab was a significant favorable
prognostic factor in the HR-positive/HER-2-negative
subgroup (AIs and/or trastuzumab for recurrent disease:
yes vs. no: HR = 0.37, P < 0.001) and the recent time per-
iod was significantly associated with prolonged survival
in the HR-positive/HER-2-positive (cohort B vs. cohort
A: HR = 0.39, P = 0.009) and HR-negative/HER-2-posi-
tive subgroups (cohort B vs. cohort A: HR = 0.12, P <
0.001). When AI/trastuzumab and the time period were
separately analyzed, each factor was a strong prognostic
factor in the HR-positive and/or HER-2-positive subtype
but not in the HR-negative and HER-2-negative subtype
in the presence of other confounders.
Discussion
In this retrospective, single-institution study, we found
that the survival of patients with recurrent breast cancer
was significantly improved after the introduction of AIs
and trastuzumab to the therapeutic regimen after 2001.
A l s o ,a ni m p r o v e dp r o g n o s i sw a ss e e ni np a t i e n t sw i t h
recurrent breast cancer that was related to HR and
HER-2 expression. Patients with HR-positive and/or
HER-2-positive tumors showed improved survival times
after 2001; however, this was not the case for patients
with HR-negative/HER-2-negative tumors.
Table 2 Chemotherapies and endocrine therapies for the











Tamoxifen 65 38* 62 26
Medroxyprogesterone
acetate
80 47* 35 15
Aromatase inhibitors 19 11* 130 55
Chemotherapy, %
Anthracyclines 81 48* 51 22
Taxanes 43 25* 110 46
Vinorelbine 4 2.4* 60 25
Capecitabine 13 7.6* 100 42
Mitomycin 82 49* 2 0.8
HER2 targeting therapy, %
Trastuzumab 5 2.9* 51 22
*P < .05.
Figure 1 Kaplan-Meier curves showing the overall survival
rates for the two cohorts from the date of diagnosis of
recurrent breast cancer.
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patients with recurrent, or metastatic, breast cancer has
improved with the introduction of new agents [9,10,23];
however, it is not clear which particular therapy has been
responsible for this improvement. Data from the French
comprehensive cancer centers shows that increased sur-
vival time is associated with HR expression by the tumor
[14]. The hypothesis that the development of endocrine
therapy has played an important role in increased survi-
val rates is supported by the results of many randomized
trials. Third-generation aromatase inhibitors (AI)
recently became available for the treatment of breast can-
cer, and a number of randomized trials in postmenopau-
sal women with advanced breast cancer have shown the
superiority of AI over standard endocrine agents such as
tamoxifen and megestrol acetate [24-26]. There seems to
Table 3 Cox univariate and multivariate analysis of the survival in recurrent breast cancer
Characteristics Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age, years
≤ 50 1 1
>50 1.01 0.80-1.29 0.91 1.06 0.82-1.36 0.66
T stage
T1-T2 1 1
T3-T4 1.56 1.20-2.04 0.001 1.41 1.05-1.89 0.02
No. of axillary nodes involved
≤ 3 nodes 1 1
>3 nodes 1.42 1.12-1.80 0.003 1.43 1.10-1.87 0.007
HR status
negative 1 1
positive 0.49 0.39 - 0.62 <0.001 0.62 0.48-0.81 <0.001
HER-2 status
negative 1 1
positive 0.80 0.60 - 1.10 0.11 0.69 0.51-0.92 0.01
Adjuvant endocrine therapy
no 1 1
yes 0.68 0.54-0.86 0.001 0.94 0.70-1.25 0.66
Adjuvant chemotherapy
no 1 1
yes 1.16 0.90-1.50 0.26 1.18 0.90-1.53 0.23
Relapse free interval
≤ 2y r 1 1
>2 yr 0.58 0.46-0.73 <0.001 0.89 0.69-1.15 0.37
Site of first recurrence
non visceral 1 1
visceral 1.77 1.40-2.24 <0.001 1.77 1.38-2.27 <0.001
Brain metastatasis at diagnosis
no 1 1
yes 1.91 1.09-3.33 0.02 2.33 1.30-4.20 0.005
AIs and/or trastuzumab for recurrent disease
no 1 1
yes 0.38 0.29-0.50 <0.001 0.46 0.33-0.63 <0.001
Time period
cohort A 1 1
cohort B 0.43 0.34 - 0.55 <0.001 0.70 0.63-0.92 0.01
Abbreviations: HR, hormone receptor; HER-2, human epidermal growth factor receptor 2; AI, aromtase inhibitors.
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AIs [22,27]. Exemestane (a steroidal AI) was shown to be
effective after the failure of other non-steroidal AIs. In
our study, a significant prolongation in survival time was
seen in patients with HR-positive tumors within cohort
B, which consisted of patients diagnosed and treated after
the 2001, the year when AIs were first approved in Japan.
This suggests that the survival rates of the HR-positive
recurrent breast cancer patients improved due to treat-
ment with AIs.
The introduction of HER-2 targeting therapies is also
thought to have played an important role in the
increased survival times. In HER-2-positive metastatic,
or advanced, breast cancer, several clinical trials showed
a significant clinical benefit of trastuzumab as a first-line
chemotherapy agent [28,29]. There is also some evi-
dence from retrospective studies that metastatic breast
cancer patients with HER-2-positve tumors benefit from
the use of trastuzumab beyond disease progression
[30,31], and a recent randomized trial showed that con-
tinuation of trastuzumab-containing treatment was asso-
ciated with a significant improvement in the overall
response rate and time to progression after disease pro-
gression in patients with HER-2-positive metastatic
breast cancer [21]. In our study, significant improve-
ments in survival times were seen in patients with HER-
2-positive tumors in cohort B, suggesting that initial, or
continued, treatment with trastuzumab was responsible.
Figure 2 Kaplan-Meier curves showing the overall survival rates for patients with (A) HR-positive/HER-2-negative, (B) HR-positive/HER-
2-positive, (C) HR-negative/HER-2-positive, and (D) HR-negative/HER-2-negative tumors within the two cohorts.
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HR-positive/HER-2-negative HR-positive/HER-2-positive HR-negative/HER-2-positive HR-negative/HER-2-negative
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age (>50 vs ≤50) 1.21 (0.85-1.73) 0.19 0.27 (0.11-0.70) 0.006 1.32 (0.47-3.73) 0.60 0.70 (0.44-1.13) 0.14
T stage (T3,4 vs T1,2) 2.00 (1.33-3.02) 0.001 2.74 (1.08-6.92) 0.03 1.40 (0.61-3.20) 0.42 1.22 (0.74-2.00) 0.44
No. of axillary nodes involved (3 < nodes vs ≤3 nodes) 1.18 (0.77-1.79) 0.45 0.93 (0.38-2.29) 0.88 2.42 (0.99-5.89) 0.054 1.52 (0.99-2.34) 0.057
HR status (positive vs negative) NA NA NA NA NA NA NA NA
HER-2 status (positive vs negative) NA NA NA NA NA NA NA NA
Adjuvant endocrine therapy (yes vs no) 1.01 (0.64-1.59) 0.98 0.72 (0.29-1.77) 0.47 NA NA NA NA
Adjuvant chemotherapy (yes vs no) 1.50 (1.03-2.19) 0.04 1.69 (0.70-4.08) 0.24 1.76 (0.68-4.53) 0.24 0.74 (0.40-1.36) 0.33
Relapse free interval (>2 yr vs ≤ 2 yr) 1.00 (0.67-1.50) 0.98 0.64 (0.30-1.37) 0.25 0.26 (0.11-0.61) 0.002 0.91 (0.55-1.52) 0.73
Site of first recurrence (visceral vs non visceral) 1.67 (1.17-2.39) 0.005 2.95 (1.36-6.41) 0.006 1.81 (0.77-4.27) 0.18 1.77 (1.12-2.79) 0.01
Brain metastatasis at diagnosis (yes vs no) 2.22 (0.68-7.27) 0.19 0.58 (0.06-5.33) 0.63 6.02 (1.87-19.3) 0.003 2.76 (0.97-7.83) 0.056
AIs and/or trastuzumab for recurrent disease (yes vs no) 0.37 (0.25-0.53) <0.001 0.55 (0.10-2.96) 0.49 0.61 (0.18-2.05) 0.42 NA NA
Time period (cohort B vs cohort A) 0.81 (0.50-1.30) 0.38 0.39 (0.19-0.79) 0.009 0.12 (0.05-0.29) <0.001 0.80 (0.50-1.29) 0.36

























































































1As shown in previous reports [9,32,33], the presence
of conventional adverse prognostic factors was shown
to be associated with poor prognosis in this study
(Table 3). The presence of visceral metastases, brain
metastasis, HR status, and T stage and the number of
axillary metastases significantly increased risk of death.
However, even after taking these prognostic factors into
account, the presence of AIs and/or trastuzumab treat-
ment significantly decreased the hazard of death in
multivariate analysis, and one could argue that the
introduction of AIs and trastuzumab made the great
contribution to the survival improvement. The time per-
iod was also shown to be a significant prognostic factor
in multivariate analysis and recent time period conferred
prolonged survival. There were also major differences
between the two cohorts in terms of the other treat-
ments received (i.e., the treatments other than AIs and
trastuzumab). Other modern cytotoxic agents such as
taxanes, capecitabine, and vinorelbine were used more
frequently in cohort B. As shown in previous reports,
the introduction of these new drugs for breast cancer
treatment appears to have improved the survival rates of
recurrent breast cancer patients [9,10]. In addition,
bisphosphonates have recently become available for the
treatment of skeletal metastases, and have been shown
to reduce the risk of bone-related events [34,35]. Pallia-
tive care has also progressed. These advances in the
treatment for recurrent breast cancer could be the rea-
son why the time period was still a significant factor in
this analysis.
As an exploratory analysis, we also investigated the
association between survival improvement and breast
cancer subtypes defined by HR and HER-2 status.
Significant survival improvements were recognized in
the HR-positive and/or HER-2-positive subtype after
introduction of AIs and trastuzumab (Figure 2). With
the introduction of these new agents, the breast cancer
subtypes became closely related to the survival of
patients with recurrent breast cancer. Regarding the
HR-negative/HER-2-negative population, our study was
underpowered in terms of demonstrating a significant
survival benefit in this subtype, and indeed the prog-
nosis was worse for this group than for the other tumor
subtypes. This subtype is reported to be associated with
aggressive behavior and poor prognosis [18,36]. In a
recent retrospective study of HR-negative/HER-2-nega-
tive breast cancer patients treated with modern che-
motherapy, the median survival time from the diagnosis
of metastatic lesions was only 13.3 months [33]. This is
far shorter than the median survival times reported in
previous studies [9,10,37]. Exploratory analysis of data
from the Cancer and Leukemia Group B 9342 study,
which tested three doses of paclitaxel in women with
advanced disease, showed that HR-negative/HER-2-
negative tumors are associated with shorter overall
survival rates compared with other subtypes [38]. Our
results showed that patients with HR-negative/HER-2-
negative tumors had no significant prolongation of sur-
vival after trastuzumab treatment; the prognosis of these
patients was only 1.4 years, even after the introduction
of AI, trastuzumab and other new agents such as
taxanes, vinorelbine and capecitabine. However, it is
important to mention that this subgroup analysis was
not part of the original study design, and that there was
not enough statistical power to lead to a definitive con-
clusion. Therefore, this finding must be interpreted with
caution.
We acknowledge that our study has several important
limitations. First, this was a retrospective study, and thus
subject to all the biases inherent to a retrospective design.
Some degree of bias was present in the unadjusted analy-
sis due to the weighting of more favorable prognostic fac-
tors, reduced number of lymph node metastases, reduced
incidence of visceral metastasis, increased incidence of
HR-positive, and longer RFI, in the groups that developed
recurrent disease in more recent years. Earlier reports
confirmed that patients with metastatic disease who had
shorter disease-free survival times, HR-negative tumors,
and visceral metastases, had significantly worse survival
rates [32]. Although the time period was shown to be a
significant prognostic factor in the multivariate analysis,
one could argue that these biases led to the survival
improvement over time. Second, only 72% of the patients
who were treated for recurrent disease were analyzed in
this single-institution retrospective study. We cannot
exclude the possibility that the analyzed population could
have been biased as compared with the original cohort.
Third, this study employed only a relatively small sample
from a single institute and thus lacked the statistical
power to lead to a definitive conclusion. Forth, informa-
tion of survival curve beyond 4 years shown in Figure 2
m a yb el i t t l ev a l u ed u et ot h el o wn u m b e r sa tr i s k .
Further examination with larger number of cases is
warranted to certify our findings.
Conclusion
In conclusion, our study suggests that the survival rates
of women with recurrent breast cancer significantly
improved after the introduction of AI and trastuzumab,
and that the survival improvement was most pronounced
in the HR-positive and/or HER-2-positive subgroup. The
prognosis for HR-negative/HER-2-negative recurrent
breast cancer patients was still poor and development of
new therapies for this population is warranted.
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